Myofascial Pain Syndromes
Muscular pain in numerous body regions that can be reproduced by pressure on TRIGGER POINTS, localized hardenings in skeletal muscle tissue. Pain is referred to a location distant from the trigger points. A prime example is the TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME.
Subtype terms (1)
More specific conditions that are subtypes of Myofascial Pain Syndromes in the MeSH hierarchy.
- Temporomandibular Joint Dysfunction Syndrome
5 drugs (4 approved, 1 experimental)
Drugs by status
Phase 4 trials (11)
Phase 3 trials (11)
Phase 2 trials (4)
Phase 1 trials (2)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (55)
- Eisai
- Cephalon
- Forest Laboratories
- AstraZeneca
- Eli Lilly
- Pfizer
- Sanofi
- Allergan
- GlaxoSmithKline
- Sunovion
- Boehringer Ingelheim
- Dr Alexander McIntyre Inc.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of Pittsburgh
- Albany Medical College
- Cleveland Sleep Research Center
- East Tennessee State University
- Duke University
- Grupo Rehabilitacion en Salud
- Henry Ford Health System
- Indiana University
- Lithuanian University of Health Sciences
- Loma Linda University
- Newton-Wellesley Hospital
- Osteoporosis Medical Center, Beverly Hills, CA
- Rutgers University
- Tufts University
- Unidad de Investigacion en Enfermedades Cronico-Degenerativas
- Universidad Autonoma de Nuevo Leon
- Universidad de Antioquia
- +25 more
Organization Involved with Phase 3 Indications (38)
- Pierre Fabre
- Jazz Pharmaceuticals
- Daiichi Sankyo
- Merck
- Merck KGaA
- Shionogi
- Ipsen
- Wyeth
- Hengrui Therapeutics, Inc.
- INC Research
- University of Arizona
- Aragon Institute of Health Sciences
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Cornell University
- Harvard University
- Federal University of Health Science of Porto Alegre
- Federal University of Rio Grande do Sul
- University of Washington
- Good Samaritan Regional Medical Center, Oregon
- Mahatma Gandhi Institute of Medical Sciences
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
- Wake Forest University
- University of Cincinnati
- Icahn School of Medicine at Mount Sinai
- Tonix Pharmaceuticals
- University of Limoges
- Hospital Egas Moniz
- Touro University
- Premier Research Group
- Sorbonne University
- +8 more
Organization Involved with Phase 2 Indications (42)
- Zars Pharma Inc.
- Chelsea Therapeutics
- Theravance
- Bausch Health Companies
- Grunenthal
- Astellas
- Aptinyx
- Virios Therapeutics
- RiboCor, Inc.
- Sosei
- Teva
- National Institutes of Health (NIH)
- National Institute of Nursing Research (NINR)
- Winnipeg Regional Health Authority
- Landstinget i Värmland
- University of Manitoba
- University of London
- Deakin University
- Hoosier Cancer Research Network
- Julius-Maximilians University
- Karlstad University
- Mahidol University
- Mansoura University
- McGill University
- Oregon Health and Science University
- University of Kentucky
- University of Kiel
- University of Rochester
- University of Southern Denmark
- Columbia University
- +12 more
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (36)
- Bioenergy Life Science, Inc.
- ESM Technologies, LLC
- IgNova GmbH
- Lescuyer Laboratory
- Alexandria University
- China Academy of Chinese Medical Sciences
- Federal University of Minas Gerais
- Haydarpasa Numune State Hospital
- Ostergotland County Council, Sweden
- Stanford University
- The Center for Clinical Research, Winston-Salem, NC
- Yonsei University
- Mayo Clinic
- Kona Research Center
- University of California, Davis
- University of California, San Francisco
- Universidad de Almeria
- Hebrew University
- University of Lyon
- Technion University
- The Annapolis Center for Effective CFS/Fibromyalgia Therapies
- Linkoping University
- CHU Charleroi
- SCOPE International AG
- Klinar CRO
- CenTrial GmbH
- Pharmasolutions4U
- Integrative Therapeutics, Inc.
- Physicians Pharmaceuticals, Inc.
- Government of Turkey
- +6 more